請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7810
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 孔繁璐(Fan-Lu Kung) | |
dc.contributor.author | Chwen-Yu Chen | en |
dc.contributor.author | 陳淳于 | zh_TW |
dc.date.accessioned | 2021-05-19T17:54:22Z | - |
dc.date.available | 2022-02-24 | |
dc.date.available | 2021-05-19T17:54:22Z | - |
dc.date.copyright | 2017-02-24 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-02-13 | |
dc.identifier.citation | 1. J. Williamson and S. LaRusse. “Genetics and genetic counseling: recommendations for Alzheimer’s disease, frontotemporal dementia, and Creutzfeldt-Jakob disease.” Current Neurology and Neuroscience Reports. 2004, 4(5), 351-357.
2. S. Brookmeyer. “Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.” American Journal of Public Health. 1998, 88(9), 1337-1342. 3. Dementia. “Fact sheet N°362.” World Health Organization. 2015. 4. A. Burns and S. Iliffe. “Alzheimer's disease.” British Medical Journal, 2009, 338. 5. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E. M. Stadlan. “Clinical diagnosis of Alzheimer’s disease.” Neurology. 1984, 939-944. 6. J. P. Michel, D. Zekry, R. Mulligan, E. Giacobini and G. Gold. “Economic considerations of Alzheimer’s disease and related disorders.” Aging Clinical and Experimental Research. 2001, 13(3), 255-260. 7. W. Henneman, J. D. Sluimer, J. Barnes, W. M. Flier, I. C. Sluimer, N. C. Fox, P. Scheltens, H. Vrenken and F. Barkhof. “Hippocampal atrophy rates in Alzheimer disease.” Neurology. 2009, 72(11), 999–1007. 8. M. Goedert. “Tau protein and neurodegeneration.” Seminars in Cell & Developmental Biology. 2004, 15, 45-49. 9. E. Storey and R. Cappai. “The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide.” Neuropathology and Applied Neurobiology. 1999, 25, 81-97. 10. C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald and K. Beyreuther. “Amyloid plaque core protein in Alzheimer disease and Down syndrome.” Proceedings of the National Academy of Sciences. 1985, 82(12), 4245-4249. 11. L. C. Walker, C. C. Ibegbu, C. W. Todd, H. L. Robinson, M. Jucker, H. LeVine III and S. Gandy. “Emerging prospects for the disease-modifying treatment of Alzheimer's disease.” Biochemical Pharmacology. 2005, 69 (7), 1001-1008. 12. J. Walter and C. Haass. “Posttranslational modifications of amyloid precursor protein in Alzheimer's disease.” Humana Press. 2000, 149-68. 13. C. Haass, C. Kaether, G. Thinakaran and S. Sisodia. “Trafficking and proteolytic processing of APP.” Cold Spring Harbor Perspectives in Medicine. 2012, 2(5). 14. E. Storey and R. Cappai. “The amyloid precursor protein of Alzheimer’s disease and the Aβ 44 peptide.” Neuropathology and Applied Neurobiology. 1999, 25 (2), 81-97. 15. R. J. O’Brien and P. C. Wong. “Amyloid precursor protein processing and Alzheimer’s disease.” Annual Review of Neuroscience. 2011, 34(1), 185-204. 16. M. Murphy and H. LeVine III. “Alzheimer’s disease and the β-Amyloid peptide.” Journal of Alzheimer’s Disease. 2010, 19(1), 311. 17. S. H. Lecker, A. L. Goldverg and W. E. Mitch. “Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.” Journal of the American Society of Nephrology. 2006, 17, 1807–1819. 18. D. Glick, S. Barth and K. F. Macleod. “Autophagy: cellular and molecular mechanisms.” The Journal of Pathology. 2010, 221(1), 3–12. 19. N. Mizushima. “Autophagy: process and function.” Genes and Development. 2007, 21(22), 2861-73. 20. C. He and D. J. Klionsky. “Regulation mechanisms and signaling pathways of autophagy.” Annual Review of Genetics. 2009, 43, 67-93. 21. G. E. Mortimore and A. R, Pösö. “Intracellular protein catabolism and its control during nutrient deprivation and supply.” Annual Review of Nutrition. 1987, 7, 539-564. 22. K. Tanaka and N. Matsuda. “Proteostasis and neurodegeneration: The roles of proteasomal degradation and autophagy.” Biochimica et Biophysica Acta. 2014, 1843(1), 197-204. 23. F. P. López, M. K. Lotz, F. J. Blanco and B. Caramés. “Autophagy activation and protection from mitochondrial dysfunction in human chondrocytes.” Arthritis & Rheumatology. 2015, 67(4), 966-76. 24. G. Yuan, S. Yan, H. Xue, P. Zhang, J. Sun and G. Li. “Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo.” The Journal of Biological Chemistry. 2014, 289, 10607-10619. 25. K. W. Kim, R. W. Mutter, C. Cao, J. M. Albert, M. Freeman, D. E. Hallahan and B. Lu. “Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling.” The Journal of Biological Chemistry. 2006, 281, 36883-36890. 26. K. Degenhardt, R. Mathew, B. Beaudoin, K. Bray, D. Anderson, G. Chen, C. Mukherjee, Y. Shi, C. Gélinas, Y. Fan, D. A. Nelson, S. Jin and E. White. “Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis.” Cancer Cell, 2006, 10, 51-64. 27. R. A. Nixon. “The role of autophagy in neurodegenerative disease.” Nature Medicine. 2013, 19, 983-997. 28. F. M. Menzies, A. Fleming and D. C. Rubinsztein. “Compromised autophagy and neurodegenerative diseases.” Nature Reviews Neuroscience. 2015, 16(6), 345-57. 29. M. C. Maiuri, E. Zalckvar, A. Kimchi, G. Kroemer. “Self-eating and self-killing: crosstalk between autophagy and apoptosis.” Nature Reviews Molecular Cell Biology. 2007, 8(9), 741-52. 30. P. Codogno and A. J. Meijer. “Autophagy and signaling: their role in cell survival and cell death.” Cell Death and Differentiation. 2005, 12, 1509-1518. 31. S. A. Tooze and T. Yoshimoiri. “The origin of the autophagosomal membrane.” Nature Cell Biology, 2010, 12(9), 831-5. 32. J. Romanov, M. Walczak, I. Ibiricu, S. Schüchner, E. Ogris, C. Kraft and S. Martens. “Mechanism and functions of membrane binding by the Atg5–Atg12/Atg16 complex during autophagosome formation.” The EMBO Journal. 2012, 31(22), 4304-4317. 33. I. Tanida and T. Ueno and E. Kominami. “LC3 and Autophagy.” Methods in Molecular Biology. 2008, 445, 77-88. 34. J. J. Lum, D. E. Bauer, M. Kong, M. H. Harris, C. Li, T. Lindsten, C. Thompson. “Growth factor regulation of autophagy and cell survival in the absence of apoptosis.” Cell. 2005, 120, 237-248. 35. G. Bjørkøy, T. Lamark, A. Brech, H. Outzen, M. Perander, A. Overvatn, H. Stenmark and T. Johansen. “p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death.” The Journal of Cell Biology. 2005, 171(4), 603–614. 36. S. Pankiv, T. H. Clausen, T. Lamark, A. Brech, J. A. Bruun, H. Outzen, A. Øvervatn, G. Bjørkøy and T. Johansen. “p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy.” The Journal of Biological Chemistry. 2007, 282, 24131-24145. 37. M. Kadowaki and M. R. Karim. “Cytosolic LC3 ratio as a quantitative index of macroautophagy.” Methods in Enzymology. 2009, 452, 199-213. 38. G. Bjørkøy, T. Lamark, S. Pankiv, A. Øvervatn, A. Brech and T. Johansen. “Monitoring autophagic degradation of p62/SQSTM1.” Methods in Enzymology. 2009, 452, 181-97. 39. H. Pugsley, S. Friend, R. Kong, S. Vaidyanathan and P. Morrissey. “Measuring autophagic flux by assessing LC3, p62 and LAMP1 co-localization using imaging flow cytometry.” The Journal of Immunology. 2015, 194(1). 40. R. C. Russell, Y. Tian, H. Yuan, H. W. Park, Y. Y. Chang, J. Kim, H. Kim, T. P. Neufeld, A. Dillin and K. L. Guan. “ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase.” Nature Cell Biology. 2013, 15(7), 741. 41. A. Salminen. “Impaired autophagy and APP processing in Alzheimer's disease: the potential role of Beclin 1 interactome.” Progress in Neurobiology. 2013, 106-107, 33-54. 42. T. Feng, P. Tammineni, C. Agrawal, Y. Y. Jeong and Q. Cai. “Autophagy-mediated regulation of BACE1 trafficking and degradation.” The Journal of Biological Chemistry. 2016. 43. C. Parr, R. Carzaniga, S. M. Gentlemen, F. V. Leuven, J. Walter and M. Sastre. “Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein.” Molecular and Cellular Biology. 2012, 32(21), 4410-4418. 44. M. E. Orr and S. Oddo. “Autophagic/lysosomal dysfunction in Alzheimer’s disease.” Alzheimer's Research & Therapy. 2013, 5(5), 53. 45. P. Nilsson, K. Loganathan, M. Sekiguchi, Y. Matsuba, K. Hui, S. Tsubuki, M. Tanaka, N. Iwata, T. Saito and T. C. Saido. “Aβ secretion and plaque formation depend on autophagy.” Cell Reports. 2013, 5(1), 61-9. 46. Z. Cai, Y. Zhou, Z. Liu, Z. Ke and B. Zhou. “Autophagy dysfunction upregulates beta-amyloid peptides via enhancing the activity of γ-secretase complex.” Journal of Neuropsychiatric Disease and Treatment. 2015, 11, 2091-2099. 47. A. Kundu, N. Milosch, P. Antonietti, F. Baumkötter, A. Zymny, U. C. Müller, S. Kins, P. Hajieva, C. Behl and D. Kögel. “Modulation of BAG3 expression and proteasomal activity by sAPPα does not require membrane-tethered holo-APP.” Molecular Neurobiology. 2016, 53(9), 5985-5994. 48. N. Milosch, G. Tanriöver, A. Kundu, A. Rami, J. C. François, F. Baumkötter, S.W. Weyer, A. Samanta, A. Jäschke, F. Brod, C. J. Buchholz, S. Kins, C. Behl, U. C. Müller and D. Kögel. “Holo-APP and G-protein-mediated signaling are required for sAPPα-induced activation of the Akt survival pathway.” Cell Death & Disease. 2014, 5(8), e1391. 49. L. Miller, R. Daum, B. Creech, D. Young, M. Downing, S. Eells, S. Pettibone, R. Hoagland and H. Chambers. “Clindamycin versus trimethoprim–sulfamethoxazole for uncomplicated skin infections.” The New England Journal of Medicine. 2015, 372(12), 1093-103. 50. R. Leclercq. “Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.” Clinical Infectious Diseases. 2002, 34(4), 482-92. 51. G. Thinakaran and E. H. Koo. “Amyloid Precursor Protein Trafficking, Processing and Function.” The Journal of Biological Chemistry. 2008, 283(44), 29615-29619. 52. A. Meléndez and B. Levine. “Autophagy in C. elegans.” WormBook. 2009. 53. N. Mizushima. “The pleiotropic role of autophagy: from protein metabolism to bactericide.” Cell Death & Differentiation. 2005, 12, 1535-41. 54. S. S. Ebada. “Methods for isolation, purification and structural elucidation of bioactive secondary metabolites from marine invertebrates.” Nature Protocols. 2008, 3(12), 1820-31. 55. H. Wang, A. Megill, K. He, A. Kirkwood and H. Lee. “Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity.” Neural Plasticity. 2012. 56. K. Kosik. “Tau Protein and Neurodegeneration.” Molecular Neurobiology. 1990, 171-79. 57. G. Glenner and C. Wong. “Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.” Biochemical and Biophysical Research Communications. 1984, 885-90. 58. I. Tanida, I. N. Minematsu, T. Ueno and E. Kominami. “Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker of autophagy.” Autophagy, 2005, 1, 84-91. 59. I. Tanida I, Y. S. Sou, J. Ezaki, I. N. Minematsu, T. Ueno and E. Kominami. “HsAtg4B/ HsApg4B/autophagin-1 cleaves the carboxyl termini of three human Atg8 homologues and delipidates microtubule-associated protein light chain 3- and GABA receptor-associated protein-phospholipid conjugates.” The Journal of Biological Chemistry. 2004, 279, 36268-76. 60. S. Barth, D. Glick and K. F. Macleod. “Autophagy: assays and artifacts.” The Journal of Pathology. 2010, 221(2), 117-124. 61. S. Kimura, N. Fujita, T. Noda and T. Yoshimori. “Monitoring autophagy in mammalian cultured cells through the dynamics of LC3.” Methods Enzymol. 2009, 452, 1-12. 62. M. Sahani, E. Itakura and N. Mizushima. “Expression of the autophagy substrate SQSTM1/p62 is restored during prolonged starvation depending on transcriptional upregulation and autophagy-derived amino acids.” Autophagy. 2014, 10(3), 431-441. 63. D. J. Klionsky et al., “Guidelines for the use and interpretation of assays for monitoring autophagy.” Autophagy. 2016, 12(1), 1-222. 64. P. Kao. “Clindamycin upregulated soluble amyloid precursor protein α through autophagy flux impairment.” National Taiwan University. 2015. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7810 | - |
dc.description.abstract | 阿茲海默氏症(Alzheimer’s disease,AD)是一類廣受重視的漸進式神經退化性疾病,其在組織病理學的特徵之一為老年斑塊。在以往的研究指出,老年斑塊主要由具有細胞毒性的Aβ的堆積所形成的。而Aβ則是APP進行β processing,經由β-secretase和γ-secretase水解後所得的產物。Aβ的生成與堆積被認為與許多因素有關,其中之一是細胞自噬。
細胞自噬是細胞在處於挨餓環境下,藉由分解一些次要的蛋白質或胞器,以應付需要和維持細胞存活的機制。近年來科學家發現,細胞自噬不僅發生在細胞營養缺乏的情況,也會在受到外來刺激或輻射導致有胞器受損(如粒線體)而威脅細胞存活時觸發,能避免細胞進行細胞凋亡而有自我保護的功用。許多與阿茲海默氏症的相關的研究中指出,當誘發細胞自噬時,會造成APP 水解產物Aβ生成量減少以及幫助清除Aβ的堆積。至於細胞自噬如何影響Aβ的生成與堆積,甚至如何調控APP的水解途徑,目前仍然不是很明確。 本研究觀察在使用克林黴素(clindamycin)之下,對於GBM8401與SH-SY5Y兩種細胞株細胞自噬的影響。從西方墨點法的結果發現,GBM8401與SH-SY5Y中的LC3-II的量皆有明顯的上升,表示在克林黴素的作用下,兩種細胞株都有細胞自噬的發生。另外,本研究也觀察了在克林黴素作用下,APP 水解途徑是否受到改變。西方墨點法的結果顯示,在GBM8401中雖然無法看到C99的訊號,但是C83的結果可能有隨著克林黴素的作用而減少的趨勢。然而,也在GBM8401的細胞培養液中發現sAPPα可能有增加的現象。綜合上述結果,本研究初步觀察到克林黴素對於細胞自噬與APP水解途徑的影響。關於在克林黴素的處理之下,APP水解途徑會如何改變以及細胞自噬與APP水解途徑改變之間的關係,仍需要進一步的研究證明。 | zh_TW |
dc.description.abstract | Alzheimer’s disease is a kind of progressive neurodegenerative diseases to which people paid much attention. One of the features of Alzheimer’s disease in histopathology is the formation of senile plaques. Early research has shown that senile plaques are formed from the aggregation of cytotoxic Aβ. Aβ is the product of amyloid precursor protein (APP) by β processing, which is cleaved by β-secretase and γ-secretase successively. Many studies have claimed that dozens of factors influence on the synthesis and clearance of Aβ, and one of which is autophagy.
Autophagy is a way by which cells are able to degrade some proteins and organelles unnecessary to meet the need and survive under starvation. Recently, scientists found that autophagy is not only switched on when cells are starving, but also when cells are under stimulation or radiation that some organelles are damaged, such as mitochondria, and survival is threatened. By autophagy, cells can prevent themselves from apoptosis. Thus, autophagy is protective. In Alzheimer’s disease, some studies show that once autophagy is induced, it leads to decreasing synthesis of Aβ and clearance of Aβ aggregation. However, how autophagy work on the synthesis and clearance of Aβ, and even how autophagy work on the alternation of APP processing pathways remains unclear. In this study, two cell lines, GBM8401 and SH-SY5Y, are used to see if autophagy is regulated under clindamycin treatment. Western blot results show that the level of LC3-II increase obviously in GBM8401 and SH-SY5Y, indicating that clindamycin induces autophagy in two cell lines. Also, GBM8401 is used to see if APP processing pathway is changed under clindamycin treatment. Western blot results show that on one hand, in cell lysate C83 may tend to decrease. On the other hand, however, sAPPα seems to increase in conditioned medium. Above all, this study shows the preliminary effect of clindamycin on autophagy and APP processing pathways. Still, further studies are needed to investigate how clindamycin change APP processing pathway and the relationship between autophagy and APP processing pathways alternation. | en |
dc.description.provenance | Made available in DSpace on 2021-05-19T17:54:22Z (GMT). No. of bitstreams: 1 ntu-106-R03423019-1.pdf: 1383845 bytes, checksum: d622ec2d0850eafc62be1676ca639003 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | ABSTRACT IV
英文縮寫表 VI 目錄 VIII 壹、序論 1 一、阿茲海默氏症 1 二、阿茲海默氏症病理研究 1 三、APP的細胞運輸和水解途徑 2 四、細胞自噬 3 五、細胞自噬的分子機制 4 六、細胞自噬與APP水解途徑 5 七、克林黴素與前人研究 5 貳、研究目的 7 參、實驗方法 8 一、觀察在克林黴素處理之下,GBM8401和SH-SY5Y是否有細胞自噬反應 8 二、觀察在克林黴素處理之下,GBM8401和SH-SY5Y的APP水解途徑的改變細胞培養 11 肆、實驗結果 13 一、觀察在克林黴素處理之下,GBM8401和SH-SY5Y細胞自噬的改變 13 二、觀察克林黴素處理之下,GBM8401和SH-SY5Y中APP水解途徑的改變 14 伍、討論 16 一、觀察在克林黴素處理之下,GBM8401和SH-SY5Y細胞自噬的改變 16 二、觀察克林黴素處理之下,GBM8401和SH-SY5Y中APP水解途徑的改變 17 陸、圖表說明 18 參考文獻 28 | |
dc.language.iso | zh-TW | |
dc.title | 探討克林黴素對細胞自噬與APP水解的影響 | zh_TW |
dc.title | Investigation of the Effect of Clindamycin on Autophagy and APP Processing | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 許麗卿(Lih-Ching Hsu),忻凌偉(Ling-Wei Hsin) | |
dc.subject.keyword | 阿茲海默氏症,克林黴素,細胞自噬,APP 水解途徑,LC3-II, | zh_TW |
dc.subject.keyword | Alzheimer’s disease,Clindamycin,Autophagy,APP Processing,LC3-II, | en |
dc.relation.page | 32 | |
dc.identifier.doi | 10.6342/NTU201700554 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2017-02-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf | 1.35 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。